Key facts
- Tioga Cardiovascular’s last known valuation is $121.0M (Sep 2025).
- It has raised $104.9M across 2 recorded rounds; the latest was Early Stage VC ($22.9M) in Aug 2025.
- Notable investors include Cormorant Asset Management, ShangBay Capital, TCP Health Ventures, AMED Ventures, PA MedTech VC Fund — 7 tracked in total.
- Tioga Cardiovascular has filed 2 Form Ds with the SEC since 2023, most recently Sep 2025 ($22.9M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tioga Cardiovascular
Funding rounds
2 roundsAbout Tioga Cardiovascular
Manufacturer of medical equipment technology intended to provide valve replacement devices for mitral applications. The company's technology is procedurally simpler and uses a less invasive, transcatheter approach, and is focused on providing a new, elegant, valve replacement solution for mitral applications, enabling doctors to perform heart surgeries effectively and successfully.
- Sector
- Healthcare
- HQ
- Los Gatos, CA, United States
- Founded
- 2012
- Employees
- 21
- Website
- tiogacardiovascular.com/
- Ownership
- Privately Held (backing)
Tioga Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tioga Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tioga Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.